C型肝炎治療のためのDAAの使い方

出版社： 文光堂
著者：
発行日： 2016-10-21
分野： 臨床医学：内科  >  肝/胆/膵
ISBN： 9784830618970
電子書籍版： 2016-10-21 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

2014年以降，高い抗ウイルス効果を持つ直接作用型抗ウイルス薬（DAA）が次々と臨床に登場し，これまで主にインターフェロン（IFN）に頼っていたC型肝炎の治療は一変した．本書は，第1・2章ではC型肝炎診療とDAAの基本的な事項について解説し， 第3章では治療対象・治療方法の選択から，処方の実際，注意すべき副作用，耐性変異，薬剤相互作用，治療後のフォローアップまでの実践的な内容を解説．C型肝炎診療に携わる肝臓内科医必読の１冊．

目次

  • C型肝炎治療のためのDAAの使い方

    ―目次―

    第1章　C型肝炎診療の基本
    　1　C型肝炎とは？ ─感染症ではなく肝疾患・全身疾患として─
    　2　C型肝炎の診断
    　3　C型肝炎の経過（自然史）
    　4　C型肝炎の治療

    第2章　DAAとは？
    　1　DAAの種類と作用機序
    　2　DAAの治療成績

    第3章　DAAによるC型肝炎治療の実際
    　1　治療対象・治療方法の選択
    　2　DAA処方の実際
    　　A　プロテアーゼ阻害薬を含む3剤併用療法
    　　B　IFN-free療法
    　　　(1) ダクラタスビル＋アスナプレビル併用療法
    　　　(2) ソホスブビル＋リバビリン併用療法
    　　　(3) ソホスブビル/レジパスビル併用療法
    　　　(4) オムビタスビル/パリタプレビル/リトナビル併用療法
    　3　副作用への対策
    　4　耐性変異への対策
    　5　薬物相互作用への注意
    　6　治療後のフォローアップ

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 C型肝炎診療の基本

P.6 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1 版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
2) Lee JJ, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One 2014 ; 9 : e100790.
PubMed
3) 日本透析医学会. 「図説わが国の慢性透析療法の現況2007年12月31日現在」. http://docs.jsdt.or.jp/overview/index2008.html
 
4) 田端秀日朗, ほか. 生体腎移植でのHCV抗体陽性レシピエントにおける腎生着率と生存率の検討. 日本透析医学会雑誌 2012 ; 45 : 1147-1153.
 
5) Younossi Z, et al. Systematic review : patientreported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015 ; 41 : 497-520.
PubMed
6) Okuse C, et al. Hepatitis C as a systemic disease : virus and host immunologic responses underlie hepatic and extrahepatic manifestations. J Gastroenterol 2007 ; 42 : 857-865.
PubMed
P.13 掲載の参考文献
1) 日本肝臓学会. 慢性肝炎・肝硬変の診療ガイド 2016. 文光堂, 2016.
 
2) 国立感染症研究所感染症情報センター. 疾患別情報C型肝炎1999年4月～2009 年 (2011年2月24日現在). http://idscnihgojp/disease/hepatitisC/2011week21html
 
3) Westbrook RH, et al. Natural history of hepatitis C. J Hepatol 2014 ; 61 : S58-S68.
PubMed
4) Thein HH, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection : a meta-analysis and meta-regression. Hepatology 2008 ; 48 : 418-431.
PubMed
5) Shiratori Y, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000 ; 132 : 517-524.
PubMed
6) Tanaka E, et al. Natural history of acute hepatitis C. J Gastroenterol Hepatol 2000 ; 15 Suppl : E97-E104.
 
7) Tanaka J, et al. Natural histories of hepatitis C virus infection in men and women simulated by the Markov model. J Med Virol 2003 ; 70 : 378-386.
 
8) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 

第2章 DAAとは ?

P.31 掲載の参考文献
1) Lohmann V, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999 ; 285 : 110-113.
 
2) Wakita T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005 ; 11 : 791-796.
PubMed
3) Lamarre D, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003 ; 426 : 186-189.
PubMed
4) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
5) Halfon P, et al. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011 ; 55 : 192-206.
PubMed
6) Gao M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010 ; 465 : 96-100.
PubMed
7) Fridell RA, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010 ; 54 : 3641-3650.
 
P.39 掲載の参考文献
1) Kumada H, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012 ; 56 : 78-84.
PubMed
2) Kumada H, et al. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan. Hepatol Res 2015 ; 45 : 745-754.
PubMed
3) Hayashi N, et al. Simeprevir with peginterferon/ ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan : CONCERTO-1, a phase III trial. J Hepatol 2014 ; 61 : 219-227.
PubMed
4) Izumi N, et al. Once-daily simeprevir with peginterferon and ribavirin for treatmentexperienced HCV genotype 1-infected patients in Japan : the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014 ; 49 : 941-953.
PubMed
5) Kumada H, et al. Simeprevir (TMC435) once daily with peginterferon-alpha-2b and ribavirin in patients with genotype 1 hepatitis C virus infection : The CONCERTO-4 study. Hepatol Res 2015 ; 45 : 501-513.
PubMed
6) Hayashi N, et al. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection : a randomized phase III study. J Gastroenterol 2016 ; 51 : 390-403.
PubMed
7) Kumada H, et al. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection : phase 3 studies. J Gastroenterol Hepatol 2016.
PubMed
8) Kumada H, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 ; 59 : 2083-2091.
PubMed
9) Mizokami M, et al. Ledipasvir and sofosbuvir fixeddose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015 ; 15 : 645-653.
PubMed
10) Kumada H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015 ; 62 : 1037-1046.
 
11) Omata M, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial. J Viral Hepat 2014 ; 21 : 762-768.
 
12) Liu CJ, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009 ; 136 : 496-504.
 
13) Liu CJ, et al. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014 ; 20 : 2955-2961.
 
14) Yu ML, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010 ; 202 : 86-92.
 
15) Collins JM, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis 2015 ; 61 : 1304-1306.
PubMed
16) De Monte A, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus : Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol 2016 ; 78 : 27-30.
PubMed
17) Takayama H, et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 2016 ; 46 : 489-491.
PubMed
18) Rockstroh JK, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION) : a non-randomised, open-label trial. Lancet HIV 2015 ; 2 : e319-327.
PubMed
19) Roth D, et al. Grazoprevir plus elbasvir in treatmentnaive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study) : a combination phase 3 study. Lancet 2015 ; 386 : 1537-1545.
 
20) Younossi ZM, et al. Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients : Results from ASTRAL-1 Placebo-Controlled Trial. J Hepatol 2016.
 
21) Feld JJ, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015 ; 373 : 2599-2607.
PubMed
22) Foster GR, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015 ; 373 : 2608-2617.
PubMed
23) Asselah T, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection : optimizing current IFN-free treatment and future perspectives. Liver Int 2016 ; 36 Suppl 1 : 47-57.
 

第3章 DAAによるC型肝炎治療の実際

P.49 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
2) Feld JJ, et al. ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015 ; 373 (27) : 2599-2607.
PubMed
3) Foster GR, et al. ASTRAL-2 Investigators ; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015 ; 373 (27) : 2608-2617.
PubMed
P.56 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
2) Driggers EM, et al. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat Rev Drug Discov 2008 ; 7 : 608-624.
PubMed
3) Furusyo N, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013 ; 59 : 205-212.
PubMed
4) Ogawa E, et al. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C. Antivir Ther 2015 ; 20 : 185-192.
PubMed
5) Ogawa E, et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat 2015 ; 22 : 992-1001.
PubMed
6) Ogawa E, et al. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol 2015 ; 30 : 1759-1767.
 
7) Liverton NJ, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010 ; 54 : 305-311.
PubMed
8) Ogawa E, et al. Efficacy of second-generation protease inhibitor-based triple therapy for chronic HCV genotype 1b patients. 25th Conference of the Asian Pacific Association for the Study of the Liver. Tokyo, 2016.
 
9) Furusyo N, et al. Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother 2011 ; 66 : 1127-1139.
PubMed
10) Furusyo N, et al. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2014 ; 69 : 483-490.
PubMed
P.64 掲載の参考文献
1) Sarrazin C, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007 ; 132 : 1767-1777.
PubMed
2) Kumada H, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012 ; 56 : 78-84.
PubMed
3) Izumi N, et al. Once-daily simeprevir with peginterferon and ribavirin for treatmentexperienced HCV genotype 1-infected patients in Japan : the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014 ; 49 : 941-953.
PubMed
4) Chopra A, et al. How to optimize HCV therapy in genotype 1 patients : management of side-effects. Liver Int 2013 ; 33 Suppl 1 : 30-34.
 
5) Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan : projection to other countries in the foreseeable future. Oncology 2002 ; 62 Suppl 1 : 8-17.
 
6) Sarrazin C, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012 ; 56 Suppl 1 : S88-100.
 
7) Lok AS, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012 ; 366 : 216-224.
PubMed
8) Chayama K, et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null-responders. Hepatology 2012 ; 55 : 742-748.
 
9) Kumada H, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 ; 59 : 2083-2091.
PubMed
10) Karino Y, et al. All-oral dual combination of daclatasvir plus asunaprevir compared with telaprevir plus peginterferon alfa/ribavirin in treatment-naive Japanese patients chronically infected with HCV genotype 1b : the AI447031 study. APASL 2015.
 
11) Halfon P, et al. Future treatment of chronic hepatitis C with direct acting antivirals : is resistance important? Liver Int 2012 ; 32 Suppl 1 : 79-87.
 
12) McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012 ; 56 : 3670-3681.
PubMed
13) Fridell RA, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 2010 ; 54 : 3641-3650.
 
14) Suzuki F, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012 ; 54 : 352-354.
PubMed
15) Suda G, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016 Jan 14. [Epub ahead of print]
 
16) Toyoda H, et al. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016 Feb 12. [Epub ahead of print]
 
17) Yalcin K, et al. A severe hepatitis flare in an HBVHCV coinfected patients during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003 ; 38 : 796-800.
 
18) Takayama H, et al. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patients with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res 2016 ; 46 : 489-491.
PubMed
19) 日本肝臓学会肝炎診療ガイドライン作成委員会. 日本肝臓学会C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidelines/hepatitis_c
 
P.72 掲載の参考文献
1) Omata M, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial. J Viral Hepat 2014 ; 21 (11) : 762-768.
 
2) Lawitz E, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013 ; 368 (20) : 1878-1887.
PubMed
3) Jacobson IM, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013 ; 368 (20) : 1867-1877.
 
P.78 掲載の参考文献
1) Matsuda F, et al. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C. J Viral Hepat 2012 ; 19 : 694-703.
 
2) Backus LI, et al. Real World Effectiveness of Ledipasvir/Sofosbuvir in 4365 Treatment-Naive Genotype 1 Hepatitis C Infected Patients. Hepatology 2016 Apr 26. doi : 10.1002/hep.28625.
 
3) Mizokami M, et al. Ledipasvir and sofosbuvir fixeddose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015 ; 15 : 645-653.
PubMed
4) ハーボニー配合錠「市販後直後調査」第5回中間報告書. http://www.pmda.go.jp/review-services/drugreviews/review-information/p-drugs/0006.html
 
5) Afdahal N, et al. No effect of proton pump inhibitor (PPI) use on SVR with ledipasvir/sofosbuvir (LDV/SOF) : real world data from 2034 genotype 1 patients in the TRIO network. J Hepatol 2016 ; LBP-519.
 
6) 日本肝臓学会肝炎診療ガイドライン作製委員会. C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
7) Nishiguchi S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001 ; 357 : 196-197.
 
P.83 掲載の参考文献
1) Chayama K, et al. Randomized trial of interferonand ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015 ; 61 : 1523-1532.
 
2) Kumada H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015 ; 62 : 1037-1046.
 
3) Kumada H, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 ; 59 : 2083-2091.
PubMed
4) Krishnan P, et al. Analysis of HCV Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir/Ritonavir and Ombitasvir. Antimicrob Agents Chemother. 2015 ; 60 : 1106-1113.
PubMed
5) ヴィキラックス(R) 配合錠添付文書.
 
P.91 掲載の参考文献
1) Fellay J, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010 ; 464 : 405-408.
PubMed
2) Ochi H, et al. ITPA polymorphism affects ribavirininduced anemia and outcomes of therapy-a genomewide study of Japanese HCV virus patients. Gastroenterology 2010 ; 139 : 1190-1197.
PubMed
3) De Franceschi L, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection : role of membrane oxidative damage. Hepatology 2000 ; 31 : 997-1004.
PubMed
4) Fujino H, et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol 2014 ; 49 : 1548-1556.
PubMed
5) Furusyo N, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013 ; 59 : 205-212.
PubMed
6) Kumada H, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 ; 59 : 2083-2091.
PubMed
7) Akuta N, et al. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol 2016 ; 88 : 506-511.
PubMed
8) Suda G, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 2016.
PubMed
9) Toyoda H, et al. Safety and efficacy of dual directacting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 2016.
 
10) Omata M, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial. J Viral Hepat 2014 ; 21 : 762-768.
 
11) Reddy KR, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis : An integrated safety and efficacy analysis. Hepatology 2015 ; 62 : 79-86.
PubMed
12) ギリアド・サイエンシズ株式会社. ハーボニー配合錠「市販直後調査」第5回中間報告. 2016.
 
13) Kumada H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015 ; 62 : 1037-1046.
 
P.100 掲載の参考文献
1) Shindo H, et al. Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hapatol Int 2012 ; 6 : 482-490.
PubMed
2) Sarrazin C, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007 ; 132 : 1767-1777.
PubMed
3) Enomoto N, et al. Mutations in the Nonstructural Protein 5a Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus 1b Infection. N Engl J Med 1995 ; 334 : 77-81.
 
4) El-Shamy A, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hapatology 2008 ; 48 : 38-47.
 
5) Maekawa S, et al. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology 2012 ; 56 : 1611-1621.
PubMed
6) Kumada H, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 ; 59 : 2083-2091.
PubMed
7) Kumada H, et al. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015 ; 62 : 1037-1046.
 
8) Sato M, et al. Deep Sequencing and Phylogenetic Analysis of Variants Resistant to Interferon-Based Protease Inhibitor Therapy in Chronic Hepatitis Induced by Genotype 1b Hepatitis C Virus. J Virol. 2015 ; 89 : 6105-6116.
PubMed
9) Akuta N, et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol 2016 [Epub ahead of print]
 
10) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
P.111 掲載の参考文献
1) Tamori A, et al. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm 2016 ; 6841628 (Epub 2016 Jan 31).
 
2) Tanaka J. Total Numbers of Undiagnosed Carriers of Hepatitis C and B Viruses in Japan Estimated by Age-and Area-Specific Prevalence on the National Scale. Intervirology 2011 ; 54 (4) : 185-195.
 
3) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
4) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5.1版). 資料2. 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
5) U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf (accessed on 2016年5月29日)
 
6) 越前宏俊. 図解薬理学-病態生理から考える薬の効くメカニズムと治療戦略 (第2版). 医学書院, 2008
 
7) Back D, et al. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013 ; 45 (Suppl 5) : S343-348.
 
P.117 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン (第5版). 2016, http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c
 
2) Ikeda K, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C : A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999 ; 29 : 1124-1130.
 
3) Yoshida H, et al. Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999 ; 131 : 174-178.
PubMed
4) Imai Y, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998 ; 129 : 94-99.
PubMed
5) Kasahara A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998 ; 27 : 1394-1402.
 
6) Okanoue T, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage : a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999 ; 30 : 653-659.
 
7) Hiramatsu N, et al. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res 2015 ; 45 : 152-161.
PubMed
8) Shiratori Y, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000 ; 132 : 517-524.
PubMed
9) Morgan RL, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma a meta-analysis of observational studies. Ann Intern Med 2013 ; 158 : 329-337.
PubMed
10) Tachi Y, et al. Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 2015 ; 45 : 238-246.
PubMed
11) Aleman S, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013 ; 57 : 230-236.
PubMed
12) Naugler WE, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007 ; 317 : 121-124.
PubMed
13) Wada K, et al. Drug Dependence and HIV/HCV Infection in Japan : The Current Situation and The CountermeasureThe Journal of AIDS Research 2011, Vol. 13, No. 1
 
14) Mathers BM, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs : a systematic review. Lancet 2008 ; 372 : 1733-1745.
PubMed
15) Nelson PK, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs : results of systematic reviews. Lancet 2011 ; 378 : 571-583.
PubMed
16) Rudd RA, et al. Increases in Drug and Opioid Overdose Deaths-United States, 2000-2014. Am J Transplant 2016 ; 16 : 1323-1327.
 
17) Wada K. The history and current state of drug abuse in Japan. Ann N Y Acad Sci 2011 ; 1216 : 62-72.
PubMed
18) 和田清, ほか. 薬物乱用・依存者におけるHIV感染と行動モニタリングに関する研究. 厚生労働科学研究費補助金 (エイズ対策研究事業) 「内外のHIV感染症の流行動向及びリスク関連情報の戦略的収集と統合的分析に関する研究 (研究代表者 : 木原正博). 平成21年度総括・分担研究報告書. 2010, p.184-201
 
19) Asahina Y, et al. Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection. Hepatology 2010 ; 52 : 518-527.
PubMed
20) Oze T, et al. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2014 ; 12 : 1186-1195.
 
21) Toyoda H, et al. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 2015 ; 30 : 1183-1189.
PubMed
22) Sasaki R, et al. Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLoS One 2015 ; 10 : e0129053.
PubMed
23) Reig M, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy : a note of caution. J Hepatol 2016.
PubMed

書評

最近チェックした商品履歴

Loading...